

IMARX THERAPEUTICS INC

Form 8-K

November 05, 2007

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): October 31, 2007**

**IMARX THERAPEUTICS, INC.**  
(Exact name of registrant as specified in its charter)

|                                                                      |                                              |                                                        |
|----------------------------------------------------------------------|----------------------------------------------|--------------------------------------------------------|
| <b>Delaware</b><br>(State or other Jurisdiction of<br>Incorporation) | <b>001-33043</b><br>(Commission File Number) | <b>86-0974730</b><br>(IRS Employer Identification No.) |
|----------------------------------------------------------------------|----------------------------------------------|--------------------------------------------------------|

|                                                                                               |                                 |
|-----------------------------------------------------------------------------------------------|---------------------------------|
| <b>1635 East 18th Street</b><br><b>Tucson, AZ</b><br>(Address of Principal Executive Offices) | <b>85719-6803</b><br>(Zip Code) |
|-----------------------------------------------------------------------------------------------|---------------------------------|

Registrant's telephone number, including area code: **(520) 770-1259**

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events.**

On November 5, 2007, ImaRx Therapeutics issued the press release attached to this report as Exhibit 99.1. The content of the press release is incorporated herein by this reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

99.1 Press Release issued by ImaRx Therapeutics, Inc. on November 5, 2007.

2

2

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 5, 2007

**IMARX THERAPEUTICS, INC.**

By: /s/ Kevin Ontiveros  
Kevin Ontiveros,  
Vice President, Legal Affairs,  
General Counsel and Secretary

3

3

---

**EXHIBIT INDEX**

| <b><u>Exhibit No.</u></b> | <b><u>Description</u></b>                                             |
|---------------------------|-----------------------------------------------------------------------|
| 99.1                      | Press Release issued by ImaRx Therapeutics, Inc. on November 5, 2007. |